Sign In
Buy ALKS
$42.76
+1.44 (+3.48%)
At Close: Jun 03, 2026
Alkermes PLC (ALKS) Stock Up 4.8% but GF Value Says Overvalued -- GF Score: 76/100
06:51pm, Thursday, 28'th May 2026
On May 28, 2026, Alkermes PLC (ALKS) shares rose 4.8% to a current price of $39.94. This price is within a 52-week range of $25.17 to $40.79, reflecting a stron
DUBLIN--(BUSINESS WIRE)--Alkermes plc (Nasdaq: ALKS) today announced plans to present clinical and real-world data related to the company's psychiatry and orexin portfolios at the American Society of
DUBLIN--(BUSINESS WIRE)--Alkermes plc (Nasdaq: ALKS) today announced the presentation of accepted research at key scientific conferences this spring related to its psychiatry products—LYBALVI® (ola
Alkermes Gains Momentum After Sleep Disorder Trial Clears Key Hurdles
02:27pm, Tuesday, 12'th May 2026
Alkermes Inc. plc (NASDAQ:ALKS) stock is trading higher on Tuesday following the announcement of positive topline results from the REVITALYZ phase 3 study evaluating LUMRYZ extended-release oral suspe
DUBLIN--(BUSINESS WIRE)--Alkermes plc (Nasdaq: ALKS) today announced positive topline results from the REVITALYZ℠ double-blind, placebo-controlled, randomized withdrawal, multicenter phase 3 study e
Alkermes Analysts Increase Their Forecasts Following Strong Q1 Results
01:54pm, Wednesday, 06'th May 2026
Alkermes (NASDAQ:ALKS) reported upbeat results for the first quarter on Tuesday.
Alkermes' Q1 Earnings & Revenues Beat Estimates, Stock Rises
01:10pm, Wednesday, 06'th May 2026
ALKS beats Q1 estimates as strong proprietary drug sales lift revenues by 28%, sending shares higher, while Lumryz adds a fresh growth driver.
Alkermes: A Sleep Medicine Platform Hidden Inside A Mature CNS Company
07:30am, Wednesday, 06'th May 2026
Alkermes is transitioning into an integrated neuroscience and sleep medicine company, highlighted by the Avadel acquisition and LUMRYZ integration. Q1 2026 results show proprietary product sales risin
Alkermes plc (ALKS) Q1 2026 Earnings Call Transcript
03:41pm, Tuesday, 05'th May 2026
Alkermes plc (ALKS) Q1 2026 Earnings Call Transcript
Alkermes (ALKS) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates
10:36am, Tuesday, 05'th May 2026
While the top- and bottom-line numbers for Alkermes (ALKS) give a sense of how the business performed in the quarter ended March 2026, it could be worth looking at how some of its key metrics compare
Alkermes (ALKS) Reports Q1 Loss, Beats Revenue Estimates
09:26am, Tuesday, 05'th May 2026
Alkermes (ALKS) came out with a quarterly loss of $0.4 per share versus the Zacks Consensus Estimate of a loss of $0.57. This compares to earnings of $0.13 per share a year ago.
Alkermes plc Reports First Quarter 2026 Financial Results
07:00am, Tuesday, 05'th May 2026
DUBLIN--(BUSINESS WIRE)--Alkermes plc (Nasdaq: ALKS) today reported financial results for the quarter ended March 31, 2026 and financial expectations for full year 2026. To view the detailed first qua
Bristol Myers Squibb (BMY) Tops Q1 Earnings and Revenue Estimates
09:30am, Thursday, 30'th Apr 2026
Bristol Myers Squibb (BMY) came out with quarterly earnings of $1.58 per share, beating the Zacks Consensus Estimate of $1.44 per share. This compares to earnings of $1.8 per share a year ago.
Earnings Preview: Alkermes (ALKS) Q1 Earnings Expected to Decline
11:09am, Tuesday, 28'th Apr 2026
Alkermes (ALKS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Wall Street Analysts Believe Alkermes (ALKS) Could Rally 29.14%: Here's is How to Trade
10:56am, Tuesday, 28'th Apr 2026
The consensus price target hints at a 29.1% upside potential for Alkermes (ALKS). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate
